m6A去甲基化酶FTO及其抑制剂在急性髓系白血病中的研究进展  

Research Progress of m6A Demethylase FTO and Its Inhibitors in Acute Myeloid Leukemia--Review

作　　者：方泽浩 郑苏莹 封蔚莹[2] FANG Ze-Hao;ZHENG Su-Ying;FENGWei-Ying(School of Medicine,Shaoxing University,Shaoxing People's Hospital,Shaoxing 312000,Zhejiang Province,China;Department of Hematology,Shaoxing People's Hospital,Shaoxing 312000,Zhejiang Province,China)

机构地区：[1]绍兴文理学院医学院,浙江绍兴312000 [2]浙江省绍兴市人民医院血液科,浙江绍兴312000

出　　处：《中国实验血液学杂志》2023年第3期902-906,共5页Journal of Experimental Hematology

基　　金：2021年浙江省医药卫生科技项目(2021KY363)。

摘　　要：肥胖相关蛋白(FTO)是一种重要的调控RNA甲基化修饰的m6A去甲基化酶,能促进急性髓细胞白血病(AML)细胞的增殖。FTO通过FTO/RARA/ASB2、FTO/m6A/CEBPA、PDGFRB/ERK等多种细胞信号通路调控AML的甲基化水平,参与AML的发生、发展、治疗以及预后。目前有研究发现,多种靶向FTO的抑制剂表现出良好的抗白血病作用,FTO的研究将为AML的治疗提供新的思路。本文就FTO在AML中的作用机制以及FTO抑制剂在AML的最新研究进展作一综述。Obesity-associated protein(FTO) is an important m6A demethylase that regulates RNA methylation modification and can promote the proliferation of acute myeloid leukemia(AML) cells. FTO regulates the methylation level of AML through multiple cellular signaling pathways such as FTO/RARA/ASB2, FTO/m6A/CEBPA, and PDGFRB/ERK, and participates in the occurrence, development, treatment and prognosis of AML. At present, studies have found that a variety of inhibitors targeting FTO have shown good anti-leukemia effects, and the study of FTO will provide new ideas for the treatment of AML. This review focus on the mechanism of action of FTO in AML and the research progress of FTO inhibitors in AML.

关 键 词：肥胖相关蛋白 急性髓系白血病 m6A去甲基化酶 

分 类 号：R733.71[医药卫生—肿瘤]